Ocugen is focused on its product, NeoCart®, a cell therapy that utilizes various aspects of Co.'s restorative cell therapy platform to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. Co.'s NeoCart Phase 3 clinical trial is designed, randomized clinical trial in North America evaluating the safety and efficacy of a restorative cell therapy to treat knee cartilage damage. Co. has a License and Commercialization Agreement with MEDINET Co., Ltd. with regards to the commercialization of NeoCart in Japan. HISTOGENICS (and design), its logo design and NEOCART are Co.'s registered trademarks.